Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Cancer|February 5, 2020
Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotypeTong Xu, Hong-Tao Li, Jenny Wei, et al.
Advanced Drug Delivery Reviews|March 20, 2018
NanoVelcro rare-cell assays for detection and characterization of circulating tumor cellsYu Jen Jan, Jie-Fu Chen, Yazhen Zhu, et al.
European Urology Oncology|April 22, 2023
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314Yi-Tsung Lu, Melissa Plets, Gareth Morrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2014
miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancerSajni Josson, Murali Gururajan, Peizhen Hu, et al.
Advanced Materials (Deerfield Beach, Fla.)|March 27, 2013
High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencingLibo Zhao, Yi-Tsung Lu, Fuqiang Li, et al.
Methods (San Diego, Calif.)|July 3, 2013
NanoVelcro Chip for CTC enumeration in prostate cancer patientsYi-Tsung Lu, Libo Zhao, Qinglin Shen, et al.
Oncotarget|November 12, 2016
Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cellsQinlong Li, Lijuan Yin, Lawrence W Jones, et al.
Cancer|May 16, 2015
Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastasesJie-Fu Chen, Hao Ho, Jake Lichterman, et al.
International Journal of Clinical Oncology|January 21, 2026
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinomaEiji Kikuchi, Michiel S Van der Heijden, Begoña P Valderrama, et al.
The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Pageof 3